BMW Ventures Ltd has opened its Initial Public Offering (IPO) yesterday on September 24, 2025. It enters its Day 2 of IPO. The bidding window for the BMW Ventures IPO will be open till September 26, 2025, for public subscription.
The allotment status for the BMW Ventures IPO is expected to be finalised on September 29, 2025, and the company shares will be listed on both BSE and NSE. The tentative listing date is expected to be October 1, 2025.
[September 25, 2025, 12:24 P.M]
On Day 2, the BMW Ventures IPO saw a subscription of 0.17 times, according to NSE data. The IPO was subscribed 0.20 times in the Retail Individual Investors (RII) category, 0.03 times in the Non-Institutional Investors (NII) category and 1.08 times in the Qualified Institutional Buyers (QIBs) category.
BMW Ventures IPO will be a bookbuilding of ₹231.66 crores. The issue is entirely a fresh issue of 2.34 crore shares. The issue price band is set at ₹94 to ₹99 per share. The minimum lot size for an application is 151 and the minimum amount required for a retail investor is ₹14,194 (151 shares).
Sarthi Capital Advisors Private Limited is the book-running lead manager, and Cameo Corporate Services Limited is the registrar for the IPO.
Check out newly Listed IPOs on BSE and NSE.
The Company will utilise the net proceeds from the issue for the following purposes:
Explore other Upcoming IPOs on BSE and NSE.
BMW Ventures Ltd, incorporated in 1994 and based in Patna, Bihar, is engaged in the trading and distribution of steel products, tractor engines, and spare parts. The company also manufactures PVC pipes, roll-formed GP sheets, pre-engineered buildings (PEBs), and steel girders. It operates through a dealer network across 29 districts in Bihar, catering to both industrial and retail clients.
BMW Ventures Ltd reported revenue of ₹128.5 crore in FY25 with a profit after tax (PAT) of ₹9.3 crore, showing steady growth over the past three years.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.